RecruitingNCT05879757

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients With Multiple Myeloma (MM) Diagnosed With Secondary Immunodeficiency (SID)

Sponsor

Takeda

Enrollment

75 participants

Start Date

Oct 17, 2023

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma Secondary Immunodeficiency (SID)

Summary

In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a real-world registry study for adults with multiple myeloma (a blood cancer) who are starting a subcutaneous immunoglobulin replacement therapy called HyQvia. HyQvia is used to prevent infections in myeloma patients whose immune system is weakened by the cancer or its treatment. This study tracks outcomes to better understand how HyQvia works in real clinical practice. **You may be eligible if...** - You are 18 or older with a diagnosis of multiple myeloma requiring systemic treatment - You have recently started HyQvia (within 30 days before or after enrollment) - You have available medical history from the time of your myeloma diagnosis - Your life expectancy is greater than 6 months **You may NOT be eligible if...** - You have a known allergy to any component of HyQvia - You have primary immunodeficiency, HIV/AIDS, or active hepatitis B or C - You received immunoglobulin treatment within the past 3 months - You are currently hospitalized for a serious infection requiring IV antibiotics - You have had an allogeneic stem cell transplant or autologous transplant within 3 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo Intervention

As this is an observational study, no intervention will be administered in this study.

Locations(27)

Instituto Privado de Investigaciones Clinicas de Cordoba

Córdoba, Argentina

Fakultni nemocnice Plzen

Pilsen, Czechia

Vseobecna fakultni Nemocnice

Prague, Czechia

CHU Amiens - Hopital Sud

Salouël, Somme, France

CHU Dijon - Hopital du Bocage

Dijon, France

Hopital Prive du Confluent

Nantes, France

Hopital de la Source - CHR Orleans

Orléans, France

CHU Bordeaux - Hopital Haut-Leveque

Pessac, France

MHP-Muenchner Haematologiepraxis

Berlin, Germany

Alexandra General Hospital

Athens, Greece

General Hospital of Thessaloniki "G. Papanikolaou"

Thessaloniki, Greece

A.O.U.C Policlinico di Bari

Bari, Italy

AOU Policlinico Rodolico San Marco

Catania, Italy

Azienda Ospedale Universita Padova

Padova, Italy

University of Padova

Treviso, Italy

Pomorski Uniwersytet Medyczny

Szczecin, Poland

Spitalul Clinic Colentina

Bucharest, Romania

Institutul Clinic Fundeni

Bucharest, Romania

Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca

Cluj-Napoca, Romania

Spitalul Clinic Municipal Filantropia Craiova

Craiova, Romania

Hospital Clinico San Carlos

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Universitari Son Espases

Palma, Spain

Lund University Hospital

Lund, Sweden

Ankara University Medical Faculty

Ankara, Turkey (Türkiye)

Antalya Training and Research Hospital

Antalya, Turkey (Türkiye)

Istanbul Universitesi

Istanbul, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05879757

Related Trials

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988874 locations

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT059471361 location

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT026826671 location

Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"

NCT048880391 location